Pharmaceutical Regulatory Consulting
Adelphi Biosciences
Credibility-first work for pharmaceutical regulatory consulting.
25+ years in enterprise IT, including Fortune 500 pharma and healthcare data platforms.
No preparation needed. You leave with next steps in writing.
- 25+ yrs enterprise IT
- Fortune 500 regulated-data environments
- Founder-led
In their words
In pharmaceutical regulatory consulting, credibility isn't optional, it's everything. The website Mark created earned it immediately. The whole experience reflects the same precision clients expect from the work itself.
Peter S. Parsonson Founder, Adelphi Biosciences
What changed
A site that establishes credibility on first contact and reflects the precision the practice's own clients expect from the work.
The situation
Adelphi Biosciences works in pharmaceutical regulatory consulting. The buyers in that field are technical, careful, and used to reading documents where a small imprecision has consequences. They evaluate a consultant the way they evaluate a submission.
That makes the website an unusual asset. It is not there to generate volume. It is there to survive a first read by somebody deciding whether this practice is rigorous enough to trust with regulatory work. In that read, the things that build credibility are unglamorous: specific language, consistency, restraint, and the absence of anything that looks approximate.
The risk is asymmetric. A site that oversells does not simply fail to persuade. In a regulated field it actively signals that the practice does not understand the standard it is claiming to meet.
What we did
The brief was credibility first, and every decision followed from that. The structure puts substance early rather than making a reader work through positioning to reach it. The language stays specific and stays inside what can be supported, because in this field restraint reads as competence and enthusiasm reads as inexperience.
Consistency was treated as a functional requirement rather than a design preference. A reader assessing rigor will notice inconsistency before they consciously register it, and they will price it in. Getting typography, spacing, and structure to hold uniformly across the site is part of the argument the site is making.
None of this is decoration. It is the same reasoning applied to a website that the client applies to a regulatory document. Say precisely what is true, present it in a form that can be checked, and do not let the presentation undercut the content.
The steps, in order
- Started from what the buyer is actually assessing: whether this practice is precise enough to trust with regulatory work.
- Built the site so the first impression matches the standard the consulting work is held to.
- Kept the language specific and restrained, because overstatement in a regulated field reads as inexperience.
- Treated design consistency as a credibility signal rather than a decorative choice.
What changed
The practice got a site that earns credibility on first contact rather than asking for it. The founder's own account is that it earned that credibility immediately, and that the experience reflects the same precision clients expect from the consulting work itself.
What it proves
This is the case that most directly explains the current work. The buyers are the same kind of people: technical, accountable, and assessing whether a supplier is careful enough to be trusted with something that carries real consequences.
Governed AI for a regulated business is judged on that basis too. Nobody in a regulated environment buys capability they cannot verify. They buy work that shows how it holds up. The medium changed. The standard did not.
What this case supports
Regulated buyers evaluate rigor before they evaluate capability. Work aimed at them has to be built for that reading.
If you need work that holds up to scrutiny, let's talk.
A twenty minute intro call is the simplest next step. No pitch, just a clear read on where you stand and what is worth doing next.
If AI is not the right tool for your problem, you will hear that from us.